Vertex at the 26th Annual North American Cystic Fibrosis Conference
Abstracts available online at the NACFC website
Orange County Convention Center | Orlando, Florida
October 11-13, 2012
Media Contacts: 617-444-6992
Dawn Kalmar
Megan Goulart
Zachry Barber
Investor Relations Contacts:
Michael Partridge (617) 444-6108
Kelly Lewis (617) 444-7530
Oral Presentations*
| October 11, 2012 10:55 a.m. EDT |
Hyperpolarized Gas MRI of Ivacaftor Therapy in Persons with Cystic Fibrosis and the G551D-CFT Mutation. Talissa Altes, M.D. |
| October 11, 2012 11:40 a.m. EDT |
The Investigational CFTR Corrector, VX-809 (Lumacaftor) Co-Administered with the Oral Potentiator Ivacaftor Improved CFTR and Lung Function in F508DEL Homozygous Patients: Phase II Study Results. Michael P. Boyle, M.D. |
*All oral presentations have an accompanying poster presentation
Poster Presentations
#30: Identification and Characterization of CFTR Corrector VRT-534 (C-18).
Peter Grootenhuis, Ph.D.
#31: Ivacaftor Potentiates Multiple Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Forms.
Frederick Van Goor, Ph.D.
#196: Hyperpolarized Gas MRI of Ivacaftor Therapy in Persons with Cystic Fibrosis and the G551D-CFTR Mutation.
Talissa Altes, M.D.
#211: Long-Term Safety and Efficacy of Ivacaftor in Persons with Cystic Fibrosis who have the G551D-CFTR Mutation.
Ed McKone, M.Sc., M.D., FRCPI, B.A., M.B., B.Ch., BAO., MRCPI
#212: Patient-Reported Outcomes in Phase 3 Trials of Ivacaftor in Subjects with CF Who Have the G551D-CFTR Mutation.
Alexandra L. Quittner, Ph.D.
#214: Nutritional Status Measures Among Persons with CF Carrying the G551D-CFTR Mutation who Received Ivacaftor or Placebo in Phase 3 Clinical Trials.
Drucy Borowitz, M.D.
#235: Exposure-Response Relationship for FEV1 and Sweat Chloride in Patients with Cystic Fibrosis Treated with Ivacaftor, a CFTR Potentiator.
Jiuhong Zha, Ph.D.
#236: Clinical Pharmacology Profile of Ivacaftor, a CFTR Potentiator.
Jiuhong Zha, Ph.D.
#249: Lung Clearance Index to Evaluate the Effect of Ivacaftor on Lung Function in Subjects with CF who have the G551D-CFTR Mutation and Mild Lung Disease.
Jane Davies, M.D., MBChB, MRCP
#260: The Investigational CFTR Corrector, VX-809 (Lumacaftor) Co-Administered with the Oral Potentiator Ivacaftor Improved CFTR and Lung Function in F508DEL Homozygous Patients: Phase II Study Results.
Michael P. Boyle, M.D.